Table 2

Incidence rates of community-acquired pneumonia (CAP), pneumococcal CAP and CAP due to vaccine and non-vaccine groups by study year

	Patient age, years	Year 6, 2013–14			Year 7, 2014–15*			Year 8, 2015–16			Year 9, 2016–17			Year 10, 2017–18
	Patient age, years	n	Incidence*	95% CI	n	Incidence*	95% CI	n	Incidence*	95% CI	n	Incidence*	95% CI	n	Incidence*	95% CI
All CAP		538	96.3	88.4 to 104.8	688	120.9	112.1 to 130.3	548	95.8	88.0 to 104.2	744	129.3	120.2 to 139.0	919	158.4	148.4 to 169.0
	16–49	91	27.3	22.0 to 33.5	117	34.8	28.8 to 41.7	114	33.7	27.8 to 40.5	112	33.0	27.1 to 39.7	102	29.9	24.4 to 36.3
	50–64	93	80.2	64.7 to 98.2	127	107.6	89.7 to 128.1	114	94.9	78.3 to 114.0	145	119.7	101.0 to 140.8	180	146.9	126.3 to 170.0
	65–74	105	181.3	148.3 to 219.5	148	248.7	210.3 to 292.2	101	164.2	133.7 to 199.5	131	210.4	175.9 to 249.6	194	310.4	268.3 to 357.3
	75–84	145	400.6	338.0 to 471.3	181	495.9	426.3 to 573.6	142	386.9	325.9 to 456.0	199	541.3	468.7 to 622.0	207	559.5	845.8 to 641.1
	≥85	104	707.5	578.1 to 857.2	115	766.7	633.0 to 920.3	77	505.4	398.9 to 631.7	157	1024·1	870.2 to 1197·5	236	1522·6	1334·5 to 1729·7
Pneumococcal CAP		180	32.2	27.7 to 37.3	200	35.2	30.5 to 40.4	166	29.0	24.8 to 33.8	247	42.9	37.7 to 48.6	282	48.6	43.1 to 54.6
	16–49	45	13.5	9.8 to 18.0	46	13.7	10.0 to 18.3	36	10.6	7.5 to 14.7	46	13.5	9.9 to 18.1	41	12.0	8.6 to 16.3
	50–64	36	31.0	21.7 to 43.0	40	33.9	24.2 to 46.2	37	30.8	21.7 to 42.5	55	45.4	34.2 to 59.1	60	49.0	37.4 to 63.0
	65–74	38	65.6	46.4 to 90.1	48	80.7	59.5 to 107.0	41	66.6	47.8 to 90.4	50	80.3	59.6 to 105.9	69	110.4	85.9-139-7
	75–84	28	77.3	51.4 to 111.8	45	123.3	89.9 to 165.0	34	92.6	64.2 to 129.5	59	160.5	122.2 to 207.0	63	170.3	130.8 to 217.8
	≥85	33	224.5	154.5 to 315.3	21	140.0	86.7 to 214.0	21	137.8	85.3 to 210.7	37	241.4	170.0 to 332.7	49	316.1	233.9 to 417.9
PCV7-serotype CAP		10	1.8	0.9 to 3.3	14	2.5	1.3 to 4.1	12	2.1	1.1 to 3.7	17	3.0	1.7 to 4.7	18	3.1	1.8 to 4.9
	16–49	1	0.3	0.0 to 1.7	2	0.6	0.1 to 2.2	3	0.9	0.2 to 2.6	2	0.6	0.1 to 2.1	1	0.3	0.0 to 1.6
	50–64	1	0.9	0.0 to 4.8	1	0.8	0.0 to 4.7	2	1.7	0.2 to 6.0	1	0.8	0.0 to 4.6	2	1.6	0.2 to 5.9
	65–74	3	5.2	1.1 to 15.1	3	5.0	1.0 to 14.7	3	4.9	1.0 to 14.2	6	9.6	3.5 to 21.0	5	8.0	2.6 to 18.7
	75–84	1	2.8	0.1 to 15.4	6	16.4	6.0 to 35.8	2	5.4	0.7 to 19.7	3	8.2	1.7 to 23.9	6	16.2	6.0 to 35.3
	≥85	4	27.2	7.4 to 69.7	2	13.3	1.6 to 48.2	2	13.1	1.6 to 47.1	5	32.6	10.6 to 76.1	4	25.8	7.0 to 66.1
PCV13non7-serotype CAP		64	11.5	8.8 to 14.6	56	9.8	7.4 to 12.8	51	8.9	6.6 to 11.7	88	15.3	12.3 to 18.8	90	15.5	12.5 to 19.1
	16–49	15	4.5	2.5 to 7.4	4	1.2	0.3 to 3.0	7	2.1	0.8 to 4.3	11	3.2	1.6 to 5.8	5	1.1	0.5 to 3.4
	50–64	15	12.9	7.2 to 21.3	8	6.8	2.9 to 13.4	11	9.2	4.6 to 16.4	14	11.6	6.3 to 19.4	23	18.8	11.9 to 28.2
	65–74	14	24.2	13.2 to 40.6	21	35.3	21.8 to 54.0	14	22.8	12.4 to 38.2	21	33.7	20.9 to 51.6	23	36.8	23.3 to 55.2
	75–84	12	33.1	17.1 to 57.9	13	35.6	19.0 to 60.9	8	21.8	9.4 to 43.0	29	78.9	52.8 to 113.3	22	59.5	37.3 to 90.0
	≥85	8	54.4	23.5 to 107.2	10	66.7	32.0 to 122.6	11	72.2	36.0 to 129.1	13	84.8	45.2 to 145.0	17	109.7	63.9 to 175.6
PPV23non13-serotype CAP		71	12.7	9.9 to 16.0	93	16.3	13.2 to 20.0	73	12.8	10.0 to 16.0	99	17.2	14.0 to 21.0	95	16.4	13.3 to 20.0
	16–49	19	5.7	3.4 to 8.9	27	8.0	5.3 to 11.7	20	5.9	3.6 to 9.1	23	6.8	4.3 to 10.2	21	6.1	3.8 to 9.4
	50–64	16	13.8	7.9 to 22.4	19	16.1	9.7 to 25.1	19	15.8	9.5 to 24.7	21	17.3	10.7 to 26.5	20	16.3	10.0 to 25.2
	65–74	13	22.5	12.0 to 38.4	17	28.6	16.6 to 45.7	16	26.0	14.9 to 42.2	20	32.1	19.6 to 49.6	22	35.2	22.1 to 53.3
	75–84	13	35.9	19.1 to 61.4	21	57.5	35.6 to 87.9	12	32.7	16.9 to 57.1	21	57.1	35.4 to 87.3	19	51.4	30.9 to 80.2
	≥85	10	68.0	32.6 to 125.1	9	60.0	27.4 to 113.9	6	39.4	14.4 to 85.7	14	91.3	49.9 to 153.2	13	83.9	44.7 to 143.4
Non-vaccine-serotype CAP		50	9.0	6.6 to 11.8	55	9.7	7.3 to 12.6	47	8.2	6.0 to 10.9	70	12.2	9.5 to 15.4	99	17.1	13.9 to 20.8
	16–49	12	3.6	1.9 to 6.3	15	4.5	2.5 to 7.4	10	3.0	1.4 to 5.4	13	3.8	2.0 to 6.5	13	3.8	2.0 to 6.5
	50–64	9	7.8	3.5 to 14.7	13	11.0	5.9 to 18.8	7	5.8	2.3 to 12.0	21	17.3	10.7 to 26.5	19	15.5	9.3 to 24.2
	65–74	12	20.7	10.7 to 36.2	13	21.8	11.6 to 37.4	11	17.9	8.9 to 32.0	12	19.3	10.0 to 33.7	25	40.0	25.9 to 59.0
	75–84	4	11.0	3.0 to 28.3	11	30.1	15.0 to 53.9	11	30.0	15.0 to 53.6	16	43.5	24.9 to 70.7	22	59.5	37.3 to 90.0
	≥85	13	88.44	47.1 to 151.2	3	20.0	4.1 to 58.4	8	52.5	22.7 to 103.4	8	52.2	22.5 to 102.8	20	129.0	78.8 to 199.3

PCV7-serotype CAP: CAP due to serotypes included in PCV7; PCV13non7-serotype CAP: CAP due to serotypes included in PCV13, excluding serotypes also included in PCV7; PPV23non13-serotype CAP: CAP due to serotypes included in PPV23, excluding serotypes also included in PCV13; non-vaccine-serotype CAP: CAP due to a) any non-PCV13-serotype, non-PPV23-serotype and b) untyped pneumococcal cases—blood culture or BINAX urinary antigen detection positive without subsequent serotype identification, or Bio-plex24 assay positive for cell wall polysaccharide only.
*Per 100 000 population.
PCV, pneumococcal conjugate vaccine.